{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T02:19:32Z","timestamp":1786760372820,"version":"build-2736575974"},"reference-count":51,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"funded by Pharmacosmos A\/S","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2020,5,3]]},"DOI":"10.1080\/17474086.2020.1738215","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T11:02:31Z","timestamp":1583319751000},"page":"557-564","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of the reported rates of hypersensitivity reactions associated with iron dextran and ferric carboxymaltose based on global data from VigiBase\u2122 and IQVIA\u2122 MIDAS\u00ae over a ten-year period from 2008 to 2017"],"prefix":"10.1080","volume":"13","author":[{"given":"Darshana","family":"Durup","sequence":"first","affiliation":[{"name":"Pharmacosmos A\/S, Medical Affairs, Holb\u00e6k, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Schaffalitzky de Muckadell","sequence":"additional","affiliation":[{"name":"Pharmacosmos A\/S, Medical Affairs, Holb\u00e6k, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claes Christian","family":"Strom","sequence":"additional","affiliation":[{"name":"Pharmacosmos A\/S, Medical Affairs, Holb\u00e6k, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,3,17]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70001-9"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2015.11.002"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-815944"},{"key":"cit0005","volume-title":"Iron deficiency anaemia: assessment, prevention, and control. A guide for programme managers","author":"World Health Organization","year":"2001"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117383"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24201"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.114.103366"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.57"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1159\/000233080"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2005.11.056"},{"key":"cit0012","first-page":"219","volume":"25","author":"Neiser S","year":"2011","journal-title":"Port J Nephrol Hypert"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh820"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13268"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92677-1"},{"key":"cit0016","unstructured":"Injectafer\u00ae (ferric carboxymaltose injection). Prescribing information; 2013 [cited 2019 Nov 12]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/203565s000lbl.pdf"},{"key":"cit0017","unstructured":"Center for Drug Evaluation and Research. Medical review of Injectafer (VIT-45, ferric carboxymaltose injection; FCM) for the treatment of iron deficiency anemia (203565Orig1s000); 2013 [cited 2019 Nov 12]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/203565Orig1s000MedR.pdf."},{"issue":"361","key":"cit0018","first-page":"829","volume":"31","author":"Prescrire editors","year":"2013","journal-title":"Rev Prescrire"},{"issue":"1","key":"cit0019","first-page":"101","volume":"27","author":"Chenaf C","year":"2013","journal-title":"Fundam Clin Pharmacol"},{"key":"cit0020","unstructured":"Swissmedic. Vigilance News; 2013:11."},{"key":"cit0021","unstructured":"Drake S. Precaution for Ferinject\u00ae vials. DrugAlert; 2018:404 [cited 2019 Nov 12]. Available from: https:\/\/www.hps.com.au\/knowledge-centre\/drugalert\/precaution-for-ferinject-vials\/."},{"key":"cit0022","unstructured":"Australian Government Department of Health. Therapeutic Goods Administration. Database of adverse event notifications \u2013 medicines. Ferinject: Medicine summary; 2018 [cited 2019 Nov 12]. Available from: http:\/\/hpscorp.boylentest.com.au\/wp-content\/uploads\/2018\/05\/20180524_daen-report.pdf."},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1923"},{"key":"cit0024","first-page":"169107","author":"Hussain I","year":"2013","journal-title":"Anemia"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1258\/om.2012.110095"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.2165\/11592140-000000000-00000"},{"key":"cit0027","unstructured":"IQVIA\u2122. ACTS 2018. IQVIA quality assurance. 2018 [cited 2019 Nov 12]. Available from: https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/publications\/acts-2018-32nd-edition.pdf."},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfi253"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1296198"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp110262"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0769-5"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-019-00868-5"},{"key":"cit0033","unstructured":"Uppsala Monitoring Centre. VigiBase: the unique global resource at the heart of the drive for safer use of medicines [cited 2019 Nov 12]. Available from: https:\/\/www.who-umc.org\/vigibase\/vigibase\/."},{"key":"cit0034","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA\u00ae). Standardised MedDRA Queries [cited 2019 Nov 12]. Available from: https:\/\/www.meddra.org\/standardised-meddra-queries."},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13805"},{"key":"cit0036","first-page":"1","volume-title":"Side-effects of anti-inflammatory drugs, advances in inflammation research","author":"Weber JCP","year":"1984"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-019-00814-5"},{"key":"cit0038","unstructured":"European Medicines Agency. Assessment report for: Iron containing intravenous (IV) medicinal products (EMA\/549569\/2013); 2013 [cited 2019 Nov 12]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/intravenous-iron-containing-medicinal-products-article-31-referral-assessment-report_en.pdf."},{"key":"cit0039","unstructured":"Uppsala Monitoring Centre. Caveat document. Statement of reservations, limitations and conditions relating to data released from VigiBase, the WHO global database of individual case safety reports (ICSRs). 2018 [cited 2019 Nov 12]. Available from: https:\/\/www.who-umc.org\/media\/164610\/umc_caveat.pdf."},{"key":"cit0040","unstructured":"European Medicines Agency. Rapid response to BMJ. Re: Pandemrix vaccine: why was the public not told of early warning signs? (EMA\/659264\/2018). 2018 [cited 2019 Nov 12]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/other\/european-medicines-agency-rapid-response-british-medical-journal-pandemrix_.pdf."},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21794"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.15572"},{"key":"cit0043","unstructured":"Therapeutics Initiative. Intravenous (IV) iron for severe iron deficiency. Vancouver, British Columbia, Canada: Therapeutics Letter; 2015. p. 97."},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24326"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.111492"},{"key":"cit0046","unstructured":"Cochrane Consumer Network. Levels of evidence [cited 2019 Nov 12]. Available from: https:\/\/consumers.cochrane.org\/levels-evidence."},{"key":"cit0047","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module IX Addendum I \u2013 Methodological aspects of signal detection from spontaneous reports of suspected adverse reactions (EMA\/209012\/2015); 2017 [cited 2019 Nov 12]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-ix-addendum-i-methodological-aspects-signal_en.pdf."},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14043"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25060"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25564"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa011"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2020.1738215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T12:54:25Z","timestamp":1620478465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2020.1738215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,17]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5,3]]}},"alternative-id":["10.1080\/17474086.2020.1738215"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2020.1738215","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-02-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}